+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Ineffective Esophageal Motility Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

  • PDF Icon

    Report

  • 280 Pages
  • June 2025
  • Region: Global
  • Fairfield Market Research
  • ID: 5915981
Description Jump to:
The global ineffective esophageal motility treatment market is experiencing robust growth, driven by increasing cases of gastroesophageal reflux disease (GERD), aging populations, and rising obesity rates. According to recent analysis, the market is projected to reach US$ 4.86 billion by 2025 and further expand to US$ 7.4 billion by 2032, progressing at a CAGR of 6.18% over the forecast period.

Market Insights

Ineffective esophageal motility is a condition marked by the weak contraction of esophageal muscles, often resulting in issues like difficulty swallowing (dysphagia), chest pain, and acid reflux. GERD is the most common underlying cause of the condition and continues to be a major contributor to the rising demand for treatment. As the prevalence of GERD and associated disorders increases across global populations, so too does the need for effective medical and surgical solutions.

Notably, drugs remain the dominant treatment approach, accounting for the vast majority of the market share due to their accessibility and effectiveness in managing symptoms of reflux and motility disorders.

Market Drivers

Several key factors are propelling market growth:

  • Rising Prevalence of GERD: Sedentary lifestyles, unhealthy dietary habits, and a growing global population with obesity are major contributors to the rising GERD cases.
  • Aging Population: With aging comes a higher likelihood of esophageal motility issues. The elderly often experience reduced saliva production and weakened esophageal muscles, creating a significant patient base.
  • Increasing Awareness and Clinical Research: Numerous clinical trials and studies focusing on advanced treatment options for GERD and esophageal motility disorders are aiding better diagnosis and treatment decision-making.
Furthermore, the correlation between asthma and GERD adds another layer of complexity and urgency, as individuals with asthma are at increased risk for reflux-related complications.

Business Opportunity

Emerging economies such as China, India, Mexico, and Brazil present substantial opportunities for market players. These regions face underserved healthcare needs, especially for chronic gastrointestinal conditions. Increasing healthcare investments, rising disposable incomes, and improvements in healthcare infrastructure are enabling greater adoption of advanced treatment options.

Moreover, the introduction of innovative technologies such as magnetic sphincter augmentation systems, minimally invasive surgical devices, and radiofrequency ablation tools is unlocking new growth avenues. Companies focusing on product innovation and long-term efficacy studies are well-positioned to gain a competitive edge.

Regional Analysis

  • United States: Holding a significant portion of the global market share, the U.S. remains at the forefront due to high obesity rates and a growing population of GERD patients. The country also leads in the adoption of advanced treatment systems and pharmaceutical interventions.
  • China: Increasing rates of dysphagia and esophageal disorders among the elderly population are boosting demand. Improved access to healthcare and a rising awareness of gastrointestinal diseases are also major contributors to market growth in China.
  • Germany: The country is witnessing rising incidences of GERD, driven by high consumption of alcohol and caffeinated beverages. These lifestyle factors are creating strong demand for both pharmaceutical and surgical interventions.

Key Players

Leading companies in the ineffective esophageal motility treatment market are focused on strategic collaborations, clinical research, and product launches. Prominent players include:

  • Johnson & Johnson
  • Mylan Pharmaceutical
  • Medigus Ltd
  • Dr. Reddy’s Laboratories Ltd
  • Torax Medical
  • Medtronic Plc
  • AstraZeneca Plc
  • Teva Pharmaceutical Industries Ltd
  • Takeda Pharmaceutical Company Limited
  • GlaxoSmithKline Plc
  • Bayer AG
  • Pfizer Inc
  • Bausch Health Companies Inc
  • Laborie
  • Mederi Therapeutics, Inc.
  • Becton, Dickinson and Company
  • EndoGastric Solutions Inc
  • Olympus
  • Pentax
These companies are heavily investing in expanding their distribution networks, gaining regulatory approvals, and improving product efficacy through R&D efforts.

Market Segmentation

By Product:

  • Devices
  • Reflux Management Systems
  • Endoscopic Pain Modulators
  • Endostaplers
  • Radiofrequency (RF) Ablation Devices
  • Myotomy
  • Drugs
  • H2 Receptor Antagonists
  • Antacids
  • Proton Pump Inhibitors
  • Dopamine Antagonists
  • Prokinetic Agents
  • Calcium Channel Blockers

By Indication:

  • Dysphagia
  • GERD
  • Burning Chest Pain
  • Achalasia

By End User:

  • Institutional Sales
  • Hospitals
  • Ambulatory Surgical Centers
  • Retail Sales
  • Retail Pharmacies
  • Drug Stores
  • Mail Order Pharmacies

By Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East and Africa

This product will be delivered within 1-3 business days.

Table of Contents

1. Executive Summary
1.1. Global Ineffective Esophageal Motility Treatment Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2025
1.5. Analyst Recommendations
2. Market Overview
2.1. Market Definitions and Segmentations
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter’s Five Forces Analysis
2.5. COVID-19 Impact Analysis
2.5.1. Supply
2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
2.7.1. World Economic Projections
2.8. PESTLE Analysis
3. Global Ineffective Esophageal Motility Treatment Market Outlook, 2019-2032
3.1. Global Ineffective Esophageal Motility Treatment Market Outlook, by Product, Value (US$ Bn), 2019-2032
3.1.1. Key Highlights
3.1.1.1. Devices
3.1.1.1.1. Reflux Management Systems
3.1.1.1.2. Endoscopic Pain Modulators
3.1.1.1.3. Endostaplers
3.1.1.1.4. Radiofrequency (RF) Ablation Devices
3.1.1.1.5. Myotomy
3.1.1.2. Drugs
3.1.1.2.1. H2 Receptor Antagonist
3.1.1.2.2. Antacids
3.1.1.2.3. Proton Pump Inhibitors
3.1.1.2.4. Dopamine Antagonist
3.1.1.2.5. Prokinetic Agents
3.1.1.2.6. Calcium Channel Blockers
3.2. Global Ineffective Esophageal Motility Treatment Market Outlook, by Indication, Value (US$ Bn), 2019-2032
3.2.1. Key Highlights
3.2.1.1. Dysphagia
3.2.1.2. GERD
3.2.1.3. Burning chest pain
3.2.1.4. Achalasia
3.3. Global Ineffective Esophageal Motility Treatment Market Outlook, by End User, Value (US$ Bn), 2019-2032
3.3.1. Key Highlights
3.3.1.1. Institutional sales
3.3.1.1.1. Hospitals
3.3.1.1.2. Ambulatory Surgical Centers
3.3.1.2. Retail Sales
3.3.1.2.1. Retail Pharmacies
3.3.1.2.2. Drug Stores
3.3.1.2.3. Mail order Pharmacies
3.4. Global Ineffective Esophageal Motility Treatment Market Outlook, by Region, Value (US$ Bn), 2019-2032
3.4.1. Key Highlights
3.4.1.1. North America
3.4.1.2. Europe
3.4.1.3. Asia Pacific
3.4.1.4. Latin America
3.4.1.5. Middle East & Africa
4. North America Ineffective Esophageal Motility Treatment Market Outlook, 2019-2032
4.1. North America Ineffective Esophageal Motility Treatment Market Outlook, by Product, Value (US$ Bn), 2019-2032
4.1.1. Key Highlights
4.1.1.1. Devices
4.1.1.1.1. Reflux Management Systems
4.1.1.1.2. Endoscopic Pain Modulators
4.1.1.1.3. Endostaplers
4.1.1.1.4. Radiofrequency (RF) Ablation Devices
4.1.1.1.5. Myotomy
4.1.1.2. Drugs
4.1.1.2.1. H2 Receptor Antagonist
4.1.1.2.2. Antacids
4.1.1.2.3. Proton Pump Inhibitors
4.1.1.2.4. Dopamine Antagonist
4.1.1.2.5. Prokinetic Agents
4.1.1.2.6. Calcium Channel Blockers
4.2. North America Ineffective Esophageal Motility Treatment Market Outlook, by Indication, Value (US$ Bn), 2019-2032
4.2.1. Key Highlights
4.2.1.1. Dysphagia
4.2.1.2. GERD
4.2.1.3. Burning chest pain
4.2.1.4. Achalasia
4.3. North America Ineffective Esophageal Motility Treatment Market Outlook, by End User, Value (US$ Bn), 2019-2032
4.3.1. Key Highlights
4.3.1.1. Institutional sales
4.3.1.1.1. Hospitals
4.3.1.1.2. Ambulatory Surgical Centers
4.3.1.2. Retail Sales
4.3.1.2.1. Retail Pharmacies
4.3.1.2.2. Drug Stores
4.3.1.2.3. Mail order Pharmacies
4.4. North America Ineffective Esophageal Motility Treatment Market Outlook, by Country, Value (US$ Bn), 2019-2032
4.4.1. Key Highlights
4.4.1.1. U.S. Ineffective Esophageal Motility Treatment Market by Product, Value (US$ Bn), 2019-2032
4.4.1.2. U.S. Ineffective Esophageal Motility Treatment Market by Indication, Value (US$ Bn), 2019-2032
4.4.1.3. U.S. Ineffective Esophageal Motility Treatment Market by End User, Value (US$ Bn), 2019-2032
4.4.1.4. Canada Ineffective Esophageal Motility Treatment Market by Product, Value (US$ Bn), 2019-2032
4.4.1.5. Canada Ineffective Esophageal Motility Treatment Market by Indication, Value (US$ Bn), 2019-2032
4.4.1.6. Canada Ineffective Esophageal Motility Treatment Market by End User, Value (US$ Bn), 2019-2032
4.4.2. BPS Analysis/Market Attractiveness Analysis
5. Europe Ineffective Esophageal Motility Treatment Market Outlook, 2019-2032
5.1. Europe Ineffective Esophageal Motility Treatment Market Outlook, by Product, Value (US$ Bn), 2019-2032
5.1.1. Key Highlights
5.1.1.1. Devices
5.1.1.1.1. Reflux Management Systems
5.1.1.1.2. Endoscopic Pain Modulators
5.1.1.1.3. Endostaplers
5.1.1.1.4. Radiofrequency (RF) Ablation Devices
5.1.1.1.5. Myotomy
5.1.1.2. Drugs
5.1.1.2.1. H2 Receptor Antagonist
5.1.1.2.2. Antacids
5.1.1.2.3. Proton Pump Inhibitors
5.1.1.2.4. Dopamine Antagonist
5.1.1.2.5. Prokinetic Agents
5.1.1.2.6. Calcium Channel Blockers
5.2. Europe Ineffective Esophageal Motility Treatment Market Outlook, by Indication, Value (US$ Bn), 2019-2032
5.2.1. Key Highlights
5.2.1.1. Dysphagia
5.2.1.2. GERD
5.2.1.3. Burning chest pain
5.2.1.4. Achalasia
5.3. Europe Ineffective Esophageal Motility Treatment Market Outlook, by End User, Value (US$ Bn), 2019-2032
5.3.1. Key Highlights
5.3.1.1. Institutional sales
5.3.1.1.1. Hospitals
5.3.1.1.2. Ambulatory Surgical Centers
5.3.1.2. Retail Sales
5.3.1.2.1. Retail Pharmacies
5.3.1.2.2. Drug Stores
5.3.1.2.3. Mail order Pharmacies
5.4. Europe Ineffective Esophageal Motility Treatment Market Outlook, by Country, Value (US$ Bn), 2019-2032
5.4.1. Key Highlights
5.4.1.1. Germany Ineffective Esophageal Motility Treatment Market by Product, Value (US$ Bn), 2019-2032
5.4.1.2. Germany Ineffective Esophageal Motility Treatment Market by Indication, Value (US$ Bn), 2019-2032
5.4.1.3. Germany Ineffective Esophageal Motility Treatment Market by End User, Value (US$ Bn), 2019-2032
5.4.1.4. U.K. Ineffective Esophageal Motility Treatment Market by Product, Value (US$ Bn), 2019-2032
5.4.1.5. U.K. Ineffective Esophageal Motility Treatment Market by Indication, Value (US$ Bn), 2019-2032
5.4.1.6. U.K. Ineffective Esophageal Motility Treatment Market by End User, Value (US$ Bn), 2019-2032
5.4.1.7. France Ineffective Esophageal Motility Treatment Market by Product, Value (US$ Bn), 2019-2032
5.4.1.8. France Ineffective Esophageal Motility Treatment Market by Indication, Value (US$ Bn), 2019-2032
5.4.1.9. France Ineffective Esophageal Motility Treatment Market by End User, Value (US$ Bn), 2019-2032
5.4.1.10. Italy Ineffective Esophageal Motility Treatment Market by Product, Value (US$ Bn), 2019-2032
5.4.1.11. Italy Ineffective Esophageal Motility Treatment Market by Indication, Value (US$ Bn), 2019-2032
5.4.1.12. Italy Ineffective Esophageal Motility Treatment Market by End User, Value (US$ Bn), 2019-2032
5.4.1.13. Turkey Ineffective Esophageal Motility Treatment Market by Product, Value (US$ Bn), 2019-2032
5.4.1.14. Turkey Ineffective Esophageal Motility Treatment Market by Indication, Value (US$ Bn), 2019-2032
5.4.1.15. Turkey Ineffective Esophageal Motility Treatment Market by End User, Value (US$ Bn), 2019-2032
5.4.1.16. Russia Ineffective Esophageal Motility Treatment Market by Product, Value (US$ Bn), 2019-2032
5.4.1.17. Russia Ineffective Esophageal Motility Treatment Market by Indication, Value (US$ Bn), 2019-2032
5.4.1.18. Russia Ineffective Esophageal Motility Treatment Market by End User, Value (US$ Bn), 2019-2032
5.4.1.19. Rest of Europe Ineffective Esophageal Motility Treatment Market by Product, Value (US$ Bn), 2019-2032
5.4.1.20. Rest of Europe Ineffective Esophageal Motility Treatment Market by Indication, Value (US$ Bn), 2019-2032
5.4.1.21. Rest of Europe Ineffective Esophageal Motility Treatment Market by End User, Value (US$ Bn), 2019-2032
5.4.2. BPS Analysis/Market Attractiveness Analysis
6. Asia Pacific Ineffective Esophageal Motility Treatment Market Outlook, 2019-2032
6.1. Asia Pacific Ineffective Esophageal Motility Treatment Market Outlook, by Product, Value (US$ Bn), 2019-2032
6.1.1. Key Highlights
6.1.1.1. Devices
6.1.1.1.1. Reflux Management Systems
6.1.1.1.2. Endoscopic Pain Modulators
6.1.1.1.3. Endostaplers
6.1.1.1.4. Radiofrequency (RF) Ablation Devices
6.1.1.1.5. Myotomy
6.1.1.2. Drugs
6.1.1.2.1. H2 Receptor Antagonist
6.1.1.2.2. Antacids
6.1.1.2.3. Proton Pump Inhibitors
6.1.1.2.4. Dopamine Antagonist
6.1.1.2.5. Prokinetic Agents
6.1.1.2.6. Calcium Channel Blockers
6.2. Asia Pacific Ineffective Esophageal Motility Treatment Market Outlook, by Indication, Value (US$ Bn), 2019-2032
6.2.1. Key Highlights
6.2.1.1. Dysphagia
6.2.1.2. GERD
6.2.1.3. Burning chest pain
6.2.1.4. Achalasia
6.3. Asia Pacific Ineffective Esophageal Motility Treatment Market Outlook, by End User, Value (US$ Bn), 2019-2032
6.3.1. Key Highlights
6.3.1.1. Institutional sales
6.3.1.1.1. Hospitals
6.3.1.1.2. Ambulatory Surgical Centers
6.3.1.2. Retail Sales
6.3.1.2.1. Retail Pharmacies
6.3.1.2.2. Drug Stores
6.3.1.2.3. Mail order Pharmacies
6.4. Asia Pacific Ineffective Esophageal Motility Treatment Market Outlook, by Country, Value (US$ Bn), 2019-2032
6.4.1. Key Highlights
6.4.1.1. China Ineffective Esophageal Motility Treatment Market by Product, Value (US$ Bn), 2019-2032
6.4.1.2. China Ineffective Esophageal Motility Treatment Market by Indication, Value (US$ Bn), 2019-2032
6.4.1.3. China Ineffective Esophageal Motility Treatment Market by End User, Value (US$ Bn), 2019-2032
6.4.1.4. Japan Ineffective Esophageal Motility Treatment Market by Product, Value (US$ Bn), 2019-2032
6.4.1.5. Japan Ineffective Esophageal Motility Treatment Market by Indication, Value (US$ Bn), 2019-2032
6.4.1.6. Japan Ineffective Esophageal Motility Treatment Market by End User, Value (US$ Bn), 2019-2032
6.4.1.7. South Korea Ineffective Esophageal Motility Treatment Market by Product, Value (US$ Bn), 2019-2032
6.4.1.8. South Korea Ineffective Esophageal Motility Treatment Market by Indication, Value (US$ Bn), 2019-2032
6.4.1.9. South Korea Ineffective Esophageal Motility Treatment Market by End User, Value (US$ Bn), 2019-2032
6.4.1.10. India Ineffective Esophageal Motility Treatment Market by Product, Value (US$ Bn), 2019-2032
6.4.1.11. India Ineffective Esophageal Motility Treatment Market by Indication, Value (US$ Bn), 2019-2032
6.4.1.12. India Ineffective Esophageal Motility Treatment Market by End User, Value (US$ Bn), 2019-2032
6.4.1.13. Southeast Asia Ineffective Esophageal Motility Treatment Market by Product, Value (US$ Bn), 2019-2032
6.4.1.14. Southeast Asia Ineffective Esophageal Motility Treatment Market by Indication, Value (US$ Bn), 2019-2032
6.4.1.15. Southeast Asia Ineffective Esophageal Motility Treatment Market by End User, Value (US$ Bn), 2019-2032
6.4.1.16. Rest of Asia Pacific Ineffective Esophageal Motility Treatment Market by Product, Value (US$ Bn), 2019-2032
6.4.1.17. Rest of Asia Pacific Ineffective Esophageal Motility Treatment Market by Indication, Value (US$ Bn), 2019-2032
6.4.1.18. Rest of Asia Pacific Ineffective Esophageal Motility Treatment Market by End User, Value (US$ Bn), 2019-2032
6.4.2. BPS Analysis/Market Attractiveness Analysis
7. Latin America Ineffective Esophageal Motility Treatment Market Outlook, 2019-2032
7.1. Latin America Ineffective Esophageal Motility Treatment Market Outlook, by Product, Value (US$ Bn), 2019-2032
7.1.1. Key Highlights
7.1.1.1. Devices
7.1.1.1.1. Reflux Management Systems
7.1.1.1.2. Endoscopic Pain Modulators
7.1.1.1.3. Endostaplers
7.1.1.1.4. Radiofrequency (RF) Ablation Devices
7.1.1.1.5. Myotomy
7.1.1.2. Drugs
7.1.1.2.1. H2 Receptor Antagonist
7.1.1.2.2. Antacids
7.1.1.2.3. Proton Pump Inhibitors
7.1.1.2.4. Dopamine Antagonist
7.1.1.2.5. Prokinetic Agents
7.1.1.2.6. Calcium Channel Blockers
7.2. Latin America Ineffective Esophageal Motility Treatment Market Outlook, by Indication, Value (US$ Bn), 2019-2032
7.2.1.1. Dysphagia
7.2.1.2. GERD
7.2.1.3. Burning chest pain
7.2.1.4. Achalasia
7.3. Latin America Ineffective Esophageal Motility Treatment Market Outlook, by End User, Value (US$ Bn), 2019-2032
7.3.1. Key Highlights
7.3.1.1. Institutional sales
7.3.1.1.1. Hospitals
7.3.1.1.2. Ambulatory Surgical Centers
7.3.1.2. Retail Sales
7.3.1.2.1. Retail Pharmacies
7.3.1.2.2. Drug Stores
7.3.1.2.3. Mail order Pharmacies
7.4. Latin America Ineffective Esophageal Motility Treatment Market Outlook, by Country, Value (US$ Bn), 2019-2032
7.4.1. Key Highlights
7.4.1.1. Brazil Ineffective Esophageal Motility Treatment Market by Product, Value (US$ Bn), 2019-2032
7.4.1.2. Brazil Ineffective Esophageal Motility Treatment Market by Indication, Value (US$ Bn), 2019-2032
7.4.1.3. Brazil Ineffective Esophageal Motility Treatment Market by End User, Value (US$ Bn), 2019-2032
7.4.1.4. Mexico Ineffective Esophageal Motility Treatment Market by Product, Value (US$ Bn), 2019-2032
7.4.1.5. Mexico Ineffective Esophageal Motility Treatment Market by Indication, Value (US$ Bn), 2019-2032
7.4.1.6. Mexico Ineffective Esophageal Motility Treatment Market by End User, Value (US$ Bn), 2019-2032
7.4.1.7. Argentina Ineffective Esophageal Motility Treatment Market by Product, Value (US$ Bn), 2019-2032
7.4.1.8. Argentina Ineffective Esophageal Motility Treatment Market by Indication, Value (US$ Bn), 2019-2032
7.4.1.9. Argentina Ineffective Esophageal Motility Treatment Market by End User, Value (US$ Bn), 2019-2032
7.4.1.10. Rest of Latin America Ineffective Esophageal Motility Treatment Market by Product, Value (US$ Bn), 2019-2032
7.4.1.11. Rest of Latin America Ineffective Esophageal Motility Treatment Market by Indication, Value (US$ Bn), 2019-2032
7.4.1.12. Rest of Latin America Ineffective Esophageal Motility Treatment Market by End User, Value (US$ Bn), 2019-2032
7.4.2. BPS Analysis/Market Attractiveness Analysis
8. Middle East & Africa Ineffective Esophageal Motility Treatment Market Outlook, 2019-2032
8.1. Middle East & Africa Ineffective Esophageal Motility Treatment Market Outlook, by Product, Value (US$ Bn), 2019-2032
8.1.1. Key Highlights
8.1.1.1. Devices
8.1.1.1.1. Reflux Management Systems
8.1.1.1.2. Endoscopic Pain Modulators
8.1.1.1.3. Endostaplers
8.1.1.1.4. Radiofrequency (RF) Ablation Devices
8.1.1.1.5. Myotomy
8.1.1.2. Drugs
8.1.1.2.1. H2 Receptor Antagonist
8.1.1.2.2. Antacids
8.1.1.2.3. Proton Pump Inhibitors
8.1.1.2.4. Dopamine Antagonist
8.1.1.2.5. Prokinetic Agents
8.1.1.2.6. Calcium Channel Blockers
8.2. Middle East & Africa Ineffective Esophageal Motility Treatment Market Outlook, by Indication, Value (US$ Bn), 2019-2032
8.2.1. Key Highlights
8.2.1.1. Dysphagia
8.2.1.2. GERD
8.2.1.3. Burning chest pain
8.2.1.4. Achalasia
8.3. Middle East & Africa Ineffective Esophageal Motility Treatment Market Outlook, by End User, Value (US$ Bn), 2019-2032
8.3.1. Key Highlights
8.3.1.1. Institutional sales
8.3.1.1.1. Hospitals
8.3.1.1.2. Ambulatory Surgical Centers
8.3.1.2. Retail Sales
8.3.1.2.1. Retail Pharmacies
8.3.1.2.2. Drug Stores
8.3.1.2.3. Mail order Pharmacies
8.4. Middle East & Africa Ineffective Esophageal Motility Treatment Market Outlook, by Country, Value (US$ Bn), 2019-2032
8.4.1. Key Highlights
8.4.1.1. GCC Ineffective Esophageal Motility Treatment Market by Product, Value (US$ Bn), 2019-2032
8.4.1.2. GCC Ineffective Esophageal Motility Treatment Market by Indication, Value (US$ Bn), 2019-2032
8.4.1.3. GCC Ineffective Esophageal Motility Treatment Market by End User, Value (US$ Bn), 2019-2032
8.4.1.4. South Africa Ineffective Esophageal Motility Treatment Market by Product, Value (US$ Bn), 2019-2032
8.4.1.5. South Africa Ineffective Esophageal Motility Treatment Market by Indication, Value (US$ Bn), 2019-2032
8.4.1.6. South Africa Ineffective Esophageal Motility Treatment Market by End User, Value (US$ Bn), 2019-2032
8.4.1.7. Egypt Ineffective Esophageal Motility Treatment Market by Product, Value (US$ Bn), 2019-2032
8.4.1.8. Egypt Ineffective Esophageal Motility Treatment Market by Indication, Value (US$ Bn), 2019-2032
8.4.1.9. Egypt Ineffective Esophageal Motility Treatment Market by End User, Value (US$ Bn), 2019-2032
8.4.1.10. Nigeria Ineffective Esophageal Motility Treatment Market by Product, Value (US$ Bn), 2019-2032
8.4.1.11. Nigeria Ineffective Esophageal Motility Treatment Market by Indication, Value (US$ Bn), 2019-2032
8.4.1.12. Nigeria Ineffective Esophageal Motility Treatment Market by End User, Value (US$ Bn), 2019-2032
8.4.1.13. Rest of Middle East & Africa Ineffective Esophageal Motility Treatment Market by Product, Value (US$ Bn), 2019-2032
8.4.1.14. Rest of Middle East & Africa Ineffective Esophageal Motility Treatment Market by Indication, Value (US$ Bn), 2019-2032
8.4.1.15. Rest of Middle East & Africa Ineffective Esophageal Motility Treatment Market by End User, Value (US$ Bn), 2019-2032
8.4.2. BPS Analysis/Market Attractiveness Analysis
9. Competitive Landscape
9.1. Product vs Indication Heatmap
9.2. Company Market Share Analysis, 2025
9.3. Competitive Dashboard
9.4. Company Profiles
9.4.1. Johnson & Johnson
9.4.1.1. Company Overview
9.4.1.2. Product Portfolio
9.4.1.3. Financial Overview
9.4.1.4. Business Strategies and Development
9.4.2. Mylan Pharmaceutical
9.4.2.1. Company Overview
9.4.2.2. Product Portfolio
9.4.2.3. Financial Overview
9.4.2.4. Business Strategies and Development
9.4.3. MediGus Ltd
9.4.3.1. Company Overview
9.4.3.2. Product Portfolio
9.4.3.3. Financial Overview
9.4.3.4. Business Strategies and Development
9.4.4. Dr. Reddy’s Laboratories Ltd.
9.4.4.1. Company Overview
9.4.4.2. Product Portfolio
9.4.4.3. Financial Overview
9.4.4.4. Business Strategies and Development
9.4.5. Torax Medical
9.4.5.1. Company Overview
9.4.5.2. Product Portfolio
9.4.5.3. Financial Overview
9.4.5.4. Business Strategies and Development
9.4.6. Medtronic Plc
9.4.6.1. Company Overview
9.4.6.2. Product Portfolio
9.4.6.3. Financial Overview
9.4.6.4. Business Strategies and Development
9.4.7. AstraZeneca Plc
9.4.7.1. Company Overview
9.4.7.2. Product Portfolio
9.4.7.3. Financial Overview
9.4.7.4. Business Strategies and Development
9.4.8. Teva Pharmaceutical Industries Ltd
9.4.8.1. Company Overview
9.4.8.2. Product Portfolio
9.4.8.3. Financial Overview
9.4.8.4. Business Strategies and Development
9.4.9. Glaxosmithkline Plc.
9.4.9.1. Company Overview
9.4.9.2. Product Portfolio
9.4.9.3. Financial Overview
9.4.9.4. Business Strategies and Development
9.4.10. Bayer Ag
9.4.10.1. Company Overview
9.4.10.2. Product Portfolio
9.4.10.3. Financial Overview
9.4.10.4. Business Strategies and Development
9.4.11. Pfixer Inc
9.4.11.1. Company Overview
9.4.11.2. Product Portfolio
9.4.11.3. Financial Overview
9.4.11.4. Business Strategies and Development
9.4.12. Bausch Health Companies Inc.
9.4.12.1. Company Overview
9.4.12.2. Product Portfolio
9.4.12.3. Financial Overview
9.4.12.4. Business Strategies and Development
9.4.13. Laborie
9.4.13.1. Company Overview
9.4.13.2. Product Portfolio
9.4.13.3. Financial Overview
9.4.13.4. Business Strategies and Development
10. Appendix
10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations

Companies Mentioned

  • Johnson & Johnson
  • Mylan Pharmaceutical
  • MediGus Ltd
  • Torax Medical
  • Medtronic Plc
  • AstraZeneca Plc
  • Teva Pharmaceutical Industries Ltd
  • Takeda Pharmaceutical Company Limited
  • Glaxosmithkline Plc.
  • Bayer Ag
  • Pfixer Inc
  • Bausch Health Companies Inc.
  • Laborie
  • Mederi Therapeutics, Inc.
  • Becton, Dickinson and Company.
  • EndoGastic Solution Inc
  • Olympus
  • Pentax

Related Topics

Related Reports

Ineffective Esophageal Motility Treatment - Global Strategic Business Report - Product Image

Ineffective Esophageal Motility Treatment - Global Strategic Business Report

  • Report
  • 371 Pages
  • Global
From
Esophageal Dysphagia Market Report 2025 - Product Image

Esophageal Dysphagia Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Gastroparesis Market - A Global and Regional Analysis: Focus on Country and Region - Analysis and Forecast, 2025-2035 - Product Image

Gastroparesis Market - A Global and Regional Analysis: Focus on Country and Region - Analysis and Forecast, 2025-2035

  • Report
  • 100 Pages
  • Global
From
Dysphagia Management Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa) - Product Image

Dysphagia Management Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

  • Report
  • 202 Pages
  • Global
From
Opioid-induced Constipation Epidemiology Forecast 2025-2034 - Product Image

Opioid-induced Constipation Epidemiology Forecast 2025-2034

  • Report
  • 150 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.